(Q43694841)

English

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

scientific article published in September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

methicillin-resistant Staphylococcus aureus

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

I Florescu

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Beuran

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

R Dimov

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A Razbadauskas

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Bochan

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

G Fichev

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

G Dukart

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

T Babinchak

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

C A Cooper

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

E J Ellis-Grosse

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

N Dartois

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

H Gandjini

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

307 Study Group

13

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

62 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

i17-28

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Current and emerging serious Gram-positive infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antibiotic resistance in Gram-positive cocci.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Life-threatening community-acquired methicillin-resistant Staphylococcus aureus infection in Australia.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Vancomycin-resistant enterococci: colonization, infection, detection, and treatment

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Treatment options for vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Impact of antibiotic resistance on clinical outcomes and the cost of care

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Tigecycline: a novel glycylcycline antibiotic

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Tigecycline for the treatment of infections due to resistant Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Overview of resistant gram-positive pathogens in the surgical patient

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antibiotic resistance in the intensive care unit

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial ag

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Grou

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

A practical guide to the treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Complicated infections of skin and skin structures: when the infection is more than skin deep

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTR

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antibiotic-resistant enterococci and the changing face of surgical infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Efficacy of linezolid versus comparator therapies in Gram-positive infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Quinupristin-dalfopristin and linezolid: evidence and opinion

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Daptomycin: the first approved lipopeptide antimicrobial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Tigecycline: a first in class glycylcycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Identifiers

10.1093/JAC/DKN250

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43694841&oldid=2102635185"